In the last trading session, 94551.0 Immix Biopharma Inc (NASDAQ:IMMX) shares changed hands as the company’s beta touched 0.27. With the company’s per share price at $2.18 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $59.97M. IMMX’s last price was a discount, traded about -242.2% off its 52-week high of $7.46. The share price had its 52-week low at $1.26, which suggests the last value was 42.2% up since then. When we look at Immix Biopharma Inc’s average trading volume, we note the 10-day average is 0.21 million shares, with the 3-month average coming to 176.54K.
Analysts gave the Immix Biopharma Inc (IMMX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMMX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Immix Biopharma Inc (NASDAQ:IMMX) trade information
The company’s shares are showing year-to-date downside of -68.50%, with the 5-day performance at -4.80% in the red. However, in the 30-day time frame, Immix Biopharma Inc (NASDAQ:IMMX) is 21.79% up. Looking at the short shares, we see there were 0.43 million shares sold at short interest cover period of 2.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 68.86% from its current market value. According to analyst projections, IMMX’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a -221.1% plunge from its current level, while the stock would need to soar -221.1% for it to hit the projected low.
Immix Biopharma Inc (IMMX) estimates and forecasts
Data shows that the Immix Biopharma Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -0.91% over the past 6 months, a 28.09% in annual growth rate that is considerably higher than the industry average of 16.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -63.30%. The 2024 estimates are for Immix Biopharma Inc earnings to increase by 14.67%.
IMMX Dividends
Immix Biopharma Inc is expected to release its next quarterly earnings report in January.
Immix Biopharma Inc (NASDAQ:IMMX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 40.10% of Immix Biopharma Inc shares while 17.64% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 29.45%. There are 17.64% institutions holding the Immix Biopharma Inc stock share, with AIGH CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 6.0017% of the shares, roughly 1.41 million IMMX shares worth $2.79 million.
BLEICHROEDER LP holds the second largest percentage of outstanding shares, with 3.6266% or 0.85 million shares worth $1.68 million as of 2024-06-30.
